Original ResearchClinical—Alimentary TractRisk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Section snippets
Patients and Methods
We analyzed the inpatient and outpatient procedural and outpatient pharmaceutical insurance claims contained in the LifeLink Health Plan Claims Database (IMS Health, Norwalk, CT) for the period January 1, 1997, through December 31, 2009. The source database contains enrollment information on more than 60 million persons from more than 98 health plans across the United States. This longitudinal, patient-level database has also been used in previous epidemiologic studies of IBD.11, 18 The
Cohort Study
The cohort study population included 108,579 patients with IBD. Of these, 50,920 had CD, 56,390 had UC, and 1269 had IBD with unknown type. There were a total of 434,233 individuals in the non-IBD comparison cohort. The median length of follow-up within this cohort was 24 months (interquartile range, 12–43), with a range from 1 to 138 months. Length of follow-up was similar for CD (35 months; interquartile range, 21–52) and UC populations (37 months; interquartile range, 22–57) while
Discussion
Over the past 2 decades, there have been important advances in the therapy of IBD, including the addition of efficacious medications such as thiopurines and biologic anti-TNF agents to the therapeutic armamentarium. These medications have allowed for dramatic improvements in maintenance of clinical remission, endoscopic remission, and quality of life for patients with IBD. As these medications are used in increasing numbers for individuals with IBD, it becomes important to understand
Acknowledgments
The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated information service(s): IMS LifeLink Health Plan Claims Database (1997–2009), IMS Health Incorporated. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary
References (42)
- et al.
Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
J Am Acad Dermatol
(1999) - et al.
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2010) - et al.
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease
Gastroenterology
(2011) - et al.
Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies
J Am Acad Dermatol
(2007) - et al.
Suboptimal rates of cervical testing among women with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2009) - et al.
Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
Respir Med
(2001) - et al.
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2006) - et al.
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Clin Gastroenterol Hepatol
(2007) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol
(1992) - et al.
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
Clin Gastroenterol Hepatol
(2009)
The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden
Gastroenterology
SEER stat fact sheets: melanoma of the skin
Cancer statistics, 2010
CA Cancer J Clin
Incidence estimate of nonmelanoma skin cancer in the United States, 2006
Arch Dermatol
The pathogenesis of melanoma induced by ultraviolet radiation
N Engl J Med
Melanoma and sun exposure: an overview of published studies
Int J Cancer
Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand
Cancer Causes Control
Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families
J Natl Cancer Inst
Skin cancers after organ transplantation
N Engl J Med
Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management
J Am Acad Dermatol
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
Gastroenterology
Cited by (422)
Cutaneous squamous cell carcinoma tumor accrual rates in immunosuppressed patients with autoimmune and inflammatory conditions: A retrospective cohort study
2024, Journal of the American Academy of DermatologyRisk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis
2024, Clinical Gastroenterology and HepatologyAcid-base transformative HADLA micelles alleviate colitis by restoring adaptive immunity and gut microbiome
2023, Journal of Controlled ReleaseRisk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study
2023, The Lancet Regional Health - EuropeHealth Care Maintenance in Pediatric Inflammatory Bowel Disease
2023, Gastroenterology Clinics of North AmericaSafety Summary of Pediatric Inflammatory Bowel Disease Therapies
2023, Gastroenterology Clinics of North America
This article has an accompanying continuing medical education activity on page e14. Learning Objective: Upon completion of this exam, successful learners will be able to interpret and communicate skin cancer risks in patients with inflammatory bowel disease (IBD).
Conflicts of interest The authors disclose no conflicts.
Funding Supported by a Career Development Award from the Crohn's and Colitis Foundation of America (M.D.L. and C.A.P.) and grants K08 DK088957-01 (to M.D.K.) and P30 DK034987 (to R.S.S.) from the National Institutes of Health.